98%
921
2 minutes
20
Background/aim: Mineralized allogeneic bone substitutes are ideal biomaterials for bone regeneration in surgeries. Moreover, they are also suitable for releasing antibiotics, delivering initial concentrations many times higher than the minimal inhibitory concentration for relevant bacterial strains, without delaying bone formation. In the present study, the potential of sustained-release long-term antibiotic delivery using allografts was investigated. A broad spectrum of antibiotics, including gentamicin, vancomycin, rifampicin, and clindamycin, was incorporated into the bone blocks using a poly-L-lactic acid (PLLA) polymer coating.
Materials And Methods: An model of implantation within the rabbit tibia plateau was used to track the sustained release of single/combined antibiotics for up to 120 days. Bony integration and tissue responses to the PLLA-coated antibiotic-delivery systems were analyzed at 4 months post implantation using histopathological analysis.
Results: The variant loaded with both vancomycin and rifampicin demonstrated the highest activity against methicillin-sensitive and . Histopathological analysis revealed that the tissue responses to the coated allogeneic bone substitutes were comparable in all study groups, with no observable histopathological differences. The coated bone blocks induced a strong foreign-body reaction, including high numbers of multinucleated giant cells and other immune cells but no material-associated bone growth.
Conclusion: Based on these results, future optimization can focus on selecting more efficient release of antibiotics and increasing the encapsulated concentration to sustain antibiotic release over 4 months, thereby improving the bacteriostatic effect . Furthermore, biocompatibility and osteoconductivity must be improved.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223631 | PMC |
http://dx.doi.org/10.21873/invivo.13987 | DOI Listing |
JAMA Pediatr
September 2025
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Importance: Neonatal intensive care has advanced over recent decades, yet premature birth remains associated with increased neonatal mortality and morbidity.
Objective: To describe health service use, morbidity, and medication needs up to age 5 years in a contemporary cohort of children born preterm.
Design, Setting, And Participants: This population-based cohort study was conducted in British Columbia (BC), Canada, using health service and pharmacy data linked using provincial administrative databases.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Cell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFTissue Eng Regen Med
September 2025
Department of Biomedical Science, Catholic Kwandong University, 24 Beomil-ro 579beon-gil, Gangneung-si, Gangwon-do, South Korea.
Background: Neurotraumatic conditions, such as spinal cord injury, brain injury, and neurodegenerative conditions, such as amyotrophic lateral sclerosis, pose a challenge to the field of rehabilitation for its complexity and nuances in management. For decades, the use of cell therapy in treatment of neurorehabilitation conditions have been explored to complement the current, mainstay treatment options; however, a consensus for standardization of the cell therapy and its efficacy has not been reached in the medical community. This study aims to provide a comparative review on the very topic of cell therapy use in neurorehabilitation conditions in an attempt to bridge the gap in knowledge.
View Article and Find Full Text PDFOsteoporos Int
September 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).
View Article and Find Full Text PDF